Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial (Q33441785)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial |
scientific article |
Statements
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial (English)
1 reference
Heidi D Klepin
1 reference
Boris Pasche
1 reference
Ralph D'Agostino
1 reference
Timothy S Pardee
1 reference
Angela Alistar
1 reference
Bonny B Morris
1 reference
Rodwige Desnoyer
1 reference
Keyanoosh Hosseinzadeh
1 reference
Clancy Clark
1 reference
Amy Cameron
1 reference
John Leyendecker
1 reference
Umit Topaloglu
1 reference
Lakmal W Boteju
1 reference
Asela R Boteju
1 reference
Rob Shorr
1 reference
Zuzana Zachar
1 reference
Paul M Bingham
1 reference
Tamjeed Ahmed
1 reference
Sandrine Crane
1 reference
Riddhishkumar Shah
1 reference
John J Migliano
1 reference
Gregory Hawkins
1 reference
Guangxu Jin
1 reference
Wei Zhang
1 reference
8 May 2017
1 reference
18
1 reference
6
1 reference
770-778
1 reference
Identifiers
1 reference